Compound | M1R Agonistic Activity pEC50 | PAM Activity Against Muscarinic Receptor Subtypes pIP | ||||||
---|---|---|---|---|---|---|---|---|
M1R | M2R | M3R | M4R | M5R | ||||
Mean | S.E.M. | Mean | S.E.M. | |||||
BQCA | 6.16 | 0.04 | 7.13 | 0.06 | <5.00 | <5.00 | <5.00 | <5.00 |
Compound A | 6.17 | 0.10 | 7.39 | 0.08 | <5.00 | <5.00 | <5.00 | <5.00 |
Compound B | 7.14 | 0.20 | 7.99 | 0.09 | <5.00 | <5.00 | 6.00 | <5.00 |
Compound C | 8.79 | 0.24 | 8.68 | 0.19 | <5.00 | <5.00 | <5.00 | <5.00 |
Compound D | 6.66 | 0.19 | 8.07 | 0.11 | <5.00 | <5.00 | <5.00 | <5.00 |
Compound E | 5.68 | 0.32 | 7.10 | 0.10 | <5.00 | <5.00 | <5.00 | <5.00 |
Compound F | <5.00 | N/A | 6.56 | 0.19 | <5.00 | <5.00 | <5.00 | <5.00 |
EC50, eliciting 50% of the maximal response of an endogenous ligand, acetylcholine (ACh), reflects the agonistic activity for M1R under conditions without ACh; IP, inflection point (PAM potency for M1-M5R, which is determined from titration of PAM in the presence of a low concentration of acetylcholine (ACh), eliciting 20% of the maximal ACh response; M1R, M1 muscarinic receptor; N/A, not available; PAM, positive allosteric modulator.